Glycinorm-M 60 OD Tablet is a fixed-dose combination medication containing Gliclazide 60 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control. This combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or on monotherapy. Glycinorm-M 60 OD is formulated as an oral dispersible tablet, facilitating ease of administration and improved patient compliance. The medication should be used as part of a comprehensive diabetes management plan, including diet and lifestyle modifications. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia due to the sulfonylurea component. Regular monitoring of blood glucose levels, renal function, and hepatic parameters is recommended during therapy. Dose adjustments may be necessary based on clinical response and tolerability. Glycinorm-M 60 OD Tablet offers an effective therapeutic option for optimizing glycemic control in type 2 diabetes mellitus.